On March 18, 2026, Catalyst Pharmaceuticals, Inc. announced that the District Court for the District of New Jersey has issued an order to delay the start of the bench trial between the company and Hetero USA, Inc. The trial, originally scheduled to commence on March 23, 2026, will now begin on May 18, 2026. This legal proceeding pertains to the validity of Catalyst's Orange Book-listed patents related to its product FIRDAPSE®, which are set to expire in 2032, 2034, and 2037. The outcome of this trial is critical for Catalyst as it seeks to protect its intellectual property rights and maintain its market position in the pharmaceutical industry. The delay may create uncertainty for investors and stakeholders, as the resolution of this legal matter could significantly impact the company's future revenue streams and market strategy. Catalyst Pharmaceuticals, headquartered in Coral Gables, Florida, is focused on developing and commercializing innovative therapies for patients with rare diseases. The company remains committed to defending its patents and ensuring the continued availability of its products to patients in need.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.